Symposium | Virtual
Event Title
Scientific Conference: Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender
September 27 - 28, 2018
- Date:
- September 27 - 28, 2018
- Time:
- 8:00 AM - 4:00 PM ET
- Organized By:
-
Organizer
Sex differences may influence susceptibility to substance abuse, which could have implications for optimal prevention and treatment. Gender influences also impact public health from an environmental perspective. To identify and treat women most at risk, researchers, educators, and clinicians must be able to recognize and consider both sex and gender differences.
The U.S. Food and Drug Administration’s Office of Women’s Health, in collaboration with the Center for Drug Evaluation and Research and the Center for Tobacco Products, will be hosting a 2-day public meeting, “Scientific Conference: Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender,” to address this important issue. The conference will include presentations by experts in the field of opioid and tobacco research, professional education, and clinical care on the biological (sex) and sociological (gender) influences on use, misuse, and recovery.
Webcast Recording Day 1- Sept 27 2018
Webcast Recording Day 2- Sept 28 2018
Keynote Speakers
Day 1
Scott Gottlieb, M.D.
Commissioner of Food and Drugs
Day 2
RADM Sylvia Trent-Adams, Ph.D, R.N., F.A.A.N.
Deputy U.S. Surgeon General
When: Thursday, September 27, 2018, and Friday, September 28, 2018, from 8:30 a.m. - 4:00 p.m.
Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender
- Conference Report: Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender (758.78 KB)
- Final Program - Scientific Conference: Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender
- Executive Summary - Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender
- Backgrounder: Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender
Executive Steering Committee (ESC)
Committee Member | Title |
---|---|
Ami Bahde, MPH | Program Analyst, FDA CTP |
Terri Cornelison, MD, PhD, FACOG | Assistant Director for the Health of Women, FDA CDRH |
Carolyn Dresler, MD, MPA | Associate Director For Medical and Health Sciences, FDA CTP |
Marjorie Jenkins, MD, MEdHP, FACP | Director of Medical Initiatives and Scientific Engagement, FDA OWH |
Tamra Meyer, PhD, MPH | Lead Epidemiologist, FDA CDER OSE |
Pamela Scott, PhD | Deputy Director, Office of Women's Health; Director of Research and Development, FDA OWH |
Jessica Tytel, MPH | Senior Advisor, HHS OWH |
Rita Valentino, PhD | Director, Division of Neuroscience and Behavior, NIH NIDA |
Cora Lee Wetherington, PhD | Women & Sex/Gender Differences Research Coordinator, NIH NIDA |
Celia Winchell, MD | Medical Officer Team Leader (addiction, drugs), FDA CDER DAAAP |
Scientific Planning Committee (SPC)
Committee Member | Title |
---|---|
Lori Bastian, MD, MPH | Professor of Internal Medicine (General Medicine); Section Chief of General Internal Medicine, VA Connecticut Healthcare System; Director, Pain Research, Informatics, Multimorbidities, and Education (PRIME) Center |
Jill Becker, PhD | Research Professor, Department of Psychiatry, Molecular and Behavioral Neuroscience Institute, University of Michigan |
Michele Bloch, MD, PhD | Chief, Tobacco Control Research Branch, Behavioral Research Program, NIH NCI |
Kathleen Brady, MD, PhD | Distinguished University Professor, Associate Provost, Clinical and Translational Science; Director, South Carolina Clinical and Translational Research Institute (SCTR), Medical University of South Carolina |
Terri Cornelison, MD, PhD, FACOG | Assistant Director for the Health of Women, FDA CDRH |
Carolyn Dresler, MD, MPA | Associate Director for Medical and Health Sciences, FDA CTP |
Phyllis E. Greenberger, MSW | Senior VP of Science and Health Policy, Healthy Women |
Gioia Guerrieri, DO | Medical Officer, CDER DAAAP |
Amber Jessup, PhD | Senior Economist, HHS ASPE |
Marjorie Jenkins, MD, MEdHP, FACP | Director of Medical Initiatives and Scientific Engagement, FDA OWH |
Hendrée Jones, PhD | Professor, Department of Obstetrics and Gynecology; Executive Director of UNC Horizons, University of North Carolina Chapel Hill School of Medicine |
Karin Mack, PhD | Science Officer, CDC |
Sherry McKee, PhD | Professor of Psychiatry; Director, Yale Behavioral Pharmacology Laboratory; Clinical Director, Forensic Drug Diversion Clinic; Director, Yale-SCOR to Develop Gender-Sensitive Therapeutics for Addiction Yale University School of Medicine |
Chad D. Morris, PhD | Associate Professor, Department of Psychiatry, Director of the Behavioral Health and Wellness Program, Co-Director of the Wellness Leadership Institute, University of Colorado |
Judith (Jodi) Prochaska, PhD, MPH | Associate Professor, Department of Medicine, Stanford University |
Jane Segebrecht, MPH | Public Health Analyst, Team Lead, HHS HRSA |
Sayeedha Uddin, MD, MPH | Senior Public Health Analyst, HHS OWH |
Cora Lee Wetherington, PhD | Women & Sex/Gender Differences Research Coordinator, NIH NIDA |
Jessica White, MPP | Social Science Analyst and CDC Team Lead, Division of Science Policy, HHS ASPE |
Scott Winiecki, MD | Lead Medical Officer, FDA CDER PASE |
Event Materials
Title | File Type/Size |
---|---|
Executive Summary - Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender | pdf (1.76 MB) |